Multicentre evaluation of a new point-of-care test for the determination of NT-proBNP in whole blood

Clinical Chemistry and Laboratory Medicine

Volumn 44, Issue 10, 2006, Pages 1269-1277

  Zugck, Christian ^a   Nelles, Manfred ^a   Katus, Hugo A ^a   Collinson, Paul O ^b   Gaze, David C ^b   Dikkeschei, Bert ^c   Gurr, Eberhard ^d   Hayen, Wiebke ^d   Haass, Markus ^e   Hechler, Christoph ^e   Van Hoof, Viviane ^f   Guerti, Khadija ^f   Van Waes, Carl ^f   Printzen, Gert ^g   Klopprogge, Kai ^h   Schulz, Ilse ⁱ   Zerback, Rainer ⁱ  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c ISALA HOSPITAL   (Netherlands)

^d Abteilung für Klinische Chemie und Zentrallabor   (Germany)

^e Theresienkrankenhaus   (Germany)

^f ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^g UNIVERSITY OF BERN   (Switzerland)

^h Exco Engineering Systemtechnik und Consulting GmbH   (Germany)

ⁱ ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Analytical performance; Brain natriuretic peptide (BNP); Congestive heart failure; N terminal proBNP (NT proBNP); Natriuretic peptides; Point of care testing

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ADRENALIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMPICILLIN; ASCORBIC ACID; BILIRUBIN; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CAPTOPRIL; CARVEDILOL; CEFOXITIN; CYCLOSPORIN; DIGITOXIN; DIGOXIN; ENALAPRIL; GENTAMICIN; HEMOGLOBIN; HEPARIN; HUMAN MONOCLONAL ANTIBODY; IBUPROFEN; INSULIN; LEVODOPA; LIDOCAINE; METHYLDOPA; PARACETAMOL; PROTEIN PRECURSOR; RHEUMATOID FACTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; ANALYTIC METHOD; ANALYTICAL ERROR; ARTERIAL BLOOD; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG COMPETITION; EVALUATION; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; LABORATORY TEST; MEASUREMENT; MULTICENTER STUDY; PATIENT MONITORING; POINT OF CARE TESTING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REFERENCE VALUE; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL; VENOUS BLOOD;

CALIBRATION; HEART DISEASES; HEART FAILURE; HEART FAILURE, CONGESTIVE; HEMOGLOBINS; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; POINT-OF-CARE SYSTEMS; REAGENT KITS, DIAGNOSTIC; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SAMPLE SIZE; TIME FACTORS;

EID: 33750054692     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2006.215     Document Type: Article

References (30)

1. Sharpe N, Doughty R. Epidemiology of heart failure and ventricular dysfunction. Lancet 1998;352(Suppl 1):3-7.
2. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure - The Framingham Heart Study. Circulation 2002;106:3068-72.
3. Nieminen MS, Böhm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, et al. Executive summary of the guidelines for the diagnosis and treatment of acute heart failure. The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:384-416.
4. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-40.
5. Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls MG, Richards AM. Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 2003;42:728-35.
6. Bayés-Genís A, Santaló-Bel M, Zapico-Muñiz E, López L, Cotes C, Bellido J, et al. N-Terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and inhospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail 2004;6:301-8.
7. Januzzi JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95:948-54.
8. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordóñez-Llanos J, Santaló-Bel M, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. Eur Heart J 2006;27:330-7.
9. Hobbs FD, Davis RC, Roalfe AK, Hare R, Davies MK, Kenkre JE. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. Br Med J 2002;324:1498-502.
10. Wright SP, Doughty RN, Pearl A, Gamble GD, Whalley GA, Walsh HJ, et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care. A randomized, controlled trial. J Am Coll Cardiol 2003;42:1793-800.
11. Bettencourt P. NT-proBNP and BNP: biomarkers for heart failure management. Eur J Heart Fail 2004;6:359-63.
12. Hartmann F, Packer M, Coats AJS, Fowler MB, Krum H, Mohacsi P, et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure. A substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial. Circulation 2004;110:1780-6.
13. Kirk V, Bay M, Parner J, Krogsgaard K, Herzog TM, Boesgaard S, et al. N-Terminal proBNP and mortality in hospitalized patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF). Eur J Heart Fail 2004;6:335-41.
14. Gardner RS, Chong KS, Morton JJ, McDonagh TA. N-Terminal brain natriuretic peptide, but not anemia, is a powerful predictor of mortality in advanced heart failure. J Card Fail 2005;11(Suppl):47-53.
15. George J, Patal S, Wexler D, Abashidze A, Shmilovich H, Barak T, et al. Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. Arch Intern Med 2005;165:1304-9.
16. Kellett J. The prediction of in-hospital mortality by amino terminal pro-brain natriuretic peptide (NT-proBNP) levels and other independent variables in acutely ill patients with suspected heart disease. Eur J Int Med 2005;16:195-9.
17. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
18. Groenning BA, Nilsson JC, Sondergaard L, Pedersen F, Trawinski J, Baumann M, et al. Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. Am Heart J 2002;143:923-9.
19. Hunt PJ, Espiner EA, Nicholls MG, Richards AM, Yandle TG. The role of the circulation in processing pro-brain natriuretic peptide (proBNP) to amino-terminal BNP and BNP-32. Peptides 1997;18:1475-81.
20. Yeo KT, Wu AH, Apple FS, Kroll MH, Christenson RH, Lewandrowski KB, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003;338:107-15.
21. van der Merwe D, Henly R, Lane G, Field R, Frenneaux M, Dunstan F, et al. Effect of different sample types and stability after blood collection of N-terminal pro-B-type natriuretic peptide as measured with Roche Elecsys System. Clin Chem 2004;50:779-80.
22. The National Academy of Clinical Biochemistry. Laboratory medicine practice guidelines: biomarkers of acute coronary syndrome and heart failure. Draft Guidelines, Version 2. http://www.nacb.org.
23. Blick KE. Economics of point-of-care (POC) testing for cardiac markers and B-natriuretic peptide (BNP). Point Care J 2005;4:11-4.
24. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350:647-54.
25. Müller-Bardorff M, Sylvén C, Rasmanis G, Jørgensen B, Collinson PO, Waldenhofer U, et al. Evaluation of a point-of-care system for quantitative determination of troponin T and myoglobin. Clin Chem Lab Med 2000;38:567-74.
26. Collinson PO, Jørgensen B, Sylvén C, Haass M, Chwallek F, Katus HA, et al. Recalibration of the point-of-care test for Cardiac T Quantitative with Elecsys Troponin T 3rd generation. Clin Chim Acta 2001;307:197-203.
27. Dempfle CE, Schraml M, Besenthal I, Hansen R, Gehrke J, Korte W, et al. Multicenter evaluation of a new point-of-care test for the quantitative determination of D-dimer. Clin Chim Acta 2001;307:211-8.
28. Collinson PO, Barnes SC, Gaze DC, Galasko G, Lahiri A, Senior R. Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail 2004;6:365-8.
29. Sokoll LJ, Baum H, Collinson PO, Gurr E, Haass M, Luthe H, et al. Multicenter analytical performance evaluation of the Elecsys proBNP assay. Clin Chem Lab Med 2004;42:965-72.
30. Fairbanks VF, Ziesmer SC, O'Brian PC. Methods for measuring plasma hemoglobin in micromolar concentration compared. Clin Chem 1992;38:132-40.